A $50 million notice letter isnt just expensiveits a warning about how a single Paragraph IV mistake can compound into real money, real delay, and real reputational damage.
If youve ever sat through a life sciences deal where counsel, business teams, a…

The At-Risk Launch: When the Math Says Go Even If the Court Says No
In branded pharma, timing isnt just strategyits math. And nowhere does that math get sharper, riskier, and more consequential than the decision to launch at risk, even when a courts a…

Evergreening isnt a conspiracyits a pattern. Heres how to spot the cracks in a 20‑patent thicket.
The pharmaceutical industry is built on timelines: filing, approvals, exclusivity, andeventuallycompetition. But in the real world, competition is often…

You dont win a patent case by chasing headlinesyou win it by turning a procedural crack into an economic outcome.
Most teams treat litigation like a binary outcome: settlement or judgment, yes or no. But theres a quieter, often overlooked strategy in t…

The 180-Day Exclusivity Trap: Why First to File Doesnt Always Win
In generics and biosimilars, the phrase first to file can sound like a cheat code.
File early, trigger 180 days of exclusivity, and reward investors with a clean lane to marketright?
Not…

Drug patent litigation is one of those domains where winning is easy to say and hard to execute. Its also where companies can accidentally train themselves to accept a costly default: assume settlements are inevitable, price the risk internally as just…

Device patents dont always get the credit they deserve in pharma strategy. But if you zoom out, they often act like the thin, decisive weakest wall in a drugs intellectual property fortress.
Heres the reality: when a challenge comes, its rarely an abst…

Most new drug patents dont create new drugs. They create new barriers.
The pharmaceutical patent system is often described as a balance: enough protection to reward innovation, enough freedom to let patients access medicines sooner. But in practice, a …

Pediatric exclusivity was sold as a shield. In practice, its often a fuseburning time, incentives, and patient access faster than the market can adapt.
For years, the U.S. pediatric exclusivity framework has been framed as a win-win: encourage companie…

Bausch Healths recent patent battle with Sun Pharma isnt just another courtroom updateits a playbook for how the next phase of branded-drug value will be defended.
And the market is already reacting.
Heres the core point: when generics and biosimilars …